` ABOS (Acumen Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

ABOS
vs
S&P 500

Over the past 12 months, ABOS has underperformed S&P 500, delivering a return of -47% compared to the S&P 500's 9% growth.

Stocks Performance
ABOS vs S&P 500

Loading
ABOS
S&P 500
Add Stock

Performance Gap
ABOS vs S&P 500

Loading
ABOS
S&P 500
Difference
www.alphaspread.com

Performance By Year
ABOS vs S&P 500

Loading
ABOS
S&P 500
Add Stock

Competitors Performance
Acumen Pharmaceuticals Inc vs Peers

S&P 500
ABOS
ABBV
AMGN
GILD
VRTX
Add Stock

Acumen Pharmaceuticals Inc
Glance View

Market Cap
73.9m USD
Industry
Biotechnology

Acumen Pharmaceuticals, Inc. discovers and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Charlottesville, Virginia and currently employs 14 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The firm's ACU193 is a humanized monoclonal antibody that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The firm's therapeutic approach focuses on targeting AbOs, which is a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques.

ABOS Intrinsic Value
3.34 USD
Undervaluation 63%
Intrinsic Value
Price
Back to Top